InsidersTradesSigma
Track the HARROW, INC. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, HARROW, INC. has logged 28 reports. Market capitalisation: €1.6bn. The latest transaction was reported on 15 May 2026 (Acquisition). Among the most active insiders: Opaleye Management Inc.. Every trade is accessible without an account.
28
Insider Decl.
n/a
Thresholds
€2m
10 ops.
Buy Volume
€2m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HARROW, INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$67.75.
55Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,036 of 29,063 companies
31.2
score / 100
Value31
Quality32
FCF yld3.1%
Earn yld-0.4%
EV/EBITDA38.8x
ROE-116%
Gross mgn75%
Net mgn-1.9%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 May 2026
Declarations28 total
3,500 shares@ US$29.900.0077% mcap50.1% of flowCommon StockSEC:0001493152-26-023319:0
Canonical exit: 12 Aug 2026 (T+90)
10,000 shares@ US$30.200.022% mcap100.0% of flowCommon StockSEC:0001493152-26-023321:0
Canonical exit: 12 Aug 2026 (T+90)
5,000 shares@ US$29.644.0% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010338:0
5,000 shares@ US$30.0114.1% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010335:0
10,000 shares@ US$25.89596.8% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010340:0
346,500 shares0Common StockSEC:0001641172-25-003112:0
762,300 shares0Common StockSEC:0001641172-25-003109:0
277,200 shares0Common StockSEC:0001641172-25-003111:0
5,000 shares@ US$30.0114.0% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-000741:0
5,000 shares@ US$29.644.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-011028:0
5,000 shares@ US$28.053.9% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-009061:0
20,000 shares@ US$35.590720.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-003670:0
90,000 shares@ US$7.3764.1% of flowCommon stockSEC:0001493152-24-036244:0
20,000 shares@ US$9.975.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015983:0
Canonical exit: 24 Jul 2024 (T+90)
11,715 shares@ US$10.293.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015806:0
Canonical exit: 22 Jul 2024 (T+90)
29,400 shares@ US$10.55758.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015410:0
Canonical exit: 18 Jul 2024 (T+90)
50,000 shares@ US$12.8217.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-011815:0
Canonical exit: 26 Jun 2024 (T+90)
9,000 shares@ US$11.594.8% of flowCommon stockSEC:0001493152-24-011071:0
Canonical exit: 20 Jun 2024 (T+90)
50,600 shares@ US$9.6513.2% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-010936:0
Canonical exit: 18 Jun 2024 (T+90)
5,000 shares@ US$8.754.3% of flowCommon stockSEC:0001493152-24-008930:0
150,000 shares@ US$10.6774.0% of flowCommon stockSEC:0001493152-24-007453:0
45,000 shares@ US$10.6765.8% of flowCommon stockSEC:0001493152-24-007454:0
30,000 shares@ US$10.6731.6% of flowCommon stockSEC:0001493152-24-007456:0
15,400 shares@ US$7.715.5% of flowCommon stockSEC:0001493152-24-005371:0
7,400 shares@ US$7.717.8% of flowCommon stockSEC:0001493152-24-005370:0
25 of 28 declarations
关于 HARROW, INC.
Harrow, Inc. (NASDAQ: HROW) 是一家总部位于美国的眼科医疗保健公司，在制药领域的一个专业但具有经济吸引力的细分市场中运营。Harrow总部位于美国田纳西州纳什维尔，最初于2012年在加利福尼亚州圣地亚哥成立，随后随着公司扩张将其公司中心迁至纳什维尔。随着时间的推移，Harrow已从一家以复合眼科药物为中心的企业发展成为一个综合平台，为眼科专业人士提供外科、诊室和慢性护理用例服务。（[investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-nashville-expansion/?utm_source=openai)） 该公司的运营模式围绕北美市场的眼科疾病管理解决方案构建。Harrow的产品组合涵盖影响眼前部和眼后部的疾病，包括干眼症、眼部炎症、白内障、青光眼、过敏性结膜炎、感染和选定的视网膜适应症。该公司通过其商业基础设施和药房关系销售品牌处方药和复合制剂的组合。Harrow重点介绍的关键产品和品牌包括VEVYE、IHEEZO、IOPIDINE、MAXITROL、MOXEZA、ILEVRO、NEVANAC、MAXIDEX、FLAREX、NATACYN、TOBRADEX ST、VERKAZIA、ZERVIATE，以及最近新增的资产如BYQLOVI。（[investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)） 从竞争角度来看，Harrow在美国眼科领域占据差异化地位，因为它结合了品牌产品、复合能力和直接商业覆盖。这种组合使公司能够接触到经常性慢性使用疗法和与手术相关的产品，同时还能够通过广泛的产品工具包支持眼科医生。Harrow将自己描述为北美眼科疾病管理解决方案的领先供应商，并继续将其平台定位于可负担性、可及性和改善临床结果。（[investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)） 最近的公司发展强调了有意的产品组合扩张战略。2024年，Harrow宣布VEVYE在美国上市，并通过340B Prime Vendor Program扩大了可及性。2025年，该公司宣布收购BYQLOVI的美国商业权利，这是一种丙酸氯倍他索滴眼液，被定位为15年多来同类中首个新型眼科类固醇。这些举措支持Harrow深化其眼科特许经营权、扩大市场准入并加强其在美国纳斯达克上市市场的商业足迹的更广泛努力。（[investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-availability-vevyer-cyclosporine-ophthalmic/?utm_source=openai)）
